On December 1st, Pfizer's official website announced the preliminary results of the Phase 2b clinical trial of the oral GLP-1R agonist Danuglipron (PF-06882961) for the treatment of obesity in adults
The results from this study highlight the critical role that glutathione homeostasis has on modulating exercise induced oxidative stress, and conversely, the effect of oxidative stress at rest on exercise induced changes in glutathione redox status[17]
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
Heart rate: Increased by an average of 57 beats per minute, consistent with other GLP-1 medications
Clinical, Cosmetic and Investigational Dermatology, 18 , 33393356
101 SunL.WangY.SongY.ChengX.XiaS.RahmanM.et al (2015)